| Name | Title | Contact Details |
|---|
Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alfa Scientific Designs, Inc is a Poway, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As a clinical-stage pharmaceutical company founded on cutting-edge research, ESSA is focused on developing novel therapeutics for cancer patients. ESSA embraces innovation not only in our products but also in our approach. We re firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.
HONOUR is a global leader in chemistry-driven solutions, focusing on the pharmaceutical, electronics, and performance materials industries. The company emphasizes innovation and agility, supported by a strong scientific workforce. HONOUR specializes in Custom Synthesis and Contract Development and Manufacturing Organization (CDMO) services, offering a range of customizable chemicals and ingredients, including coupling reagents, excipients, and polymer monomers. The Research & Development team at HONOUR combines advanced chemistry and technology to create practical solutions tailored to the unique needs of its partners. The company values trust and integrity in its relationships, aiming to foster sustainable progress in collaboration with its clients. HONOUR serves a diverse clientele, including pharmaceutical companies and electronics manufacturers, providing them with expert R&D capabilities and customized chemical solutions.
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.